ClinicalTrials.gg
RecruitingNCT07647328SERAFA-1Updated Oct 19, 2026

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

A Phase 3 interventional study of Camizestrant and Ribociclib in ER-Positive HER2-Negative Breast Cancer, sponsored by AstraZeneca. Recruiting at 89 sites in 9 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 19, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Neoplasm Metastasis by AstraZeneca — 6 open to participants now, 23 under way, 14 of them phase 3. Neoplasm Metastasis · AstraZeneca.

Planned enrollment
26th of 55
150 · median 102
Started
2026
the only one that year
Phase 3
19 of 60
4 open now
Primary completion
2029-02
later than 21 of 22 live
Registered
60th of 60
by date

Among the 60 studies in Neoplasm Metastasis by AstraZeneca, this one is the 26th largest by planned enrollment of the 55 interventional ones that give a count, is the only one that started in 2026, is one of 19 in phase 3, reaches primary completion later than 21 of the 22 other live ones, and was the 60th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

6 of the 60 studies in Neoplasm Metastasis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Neoplasm Metastasis by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial until they discontinue the study treatment for any reason.

Read the detailed description

This global, multicenter, Phase IIIb, single-arm study will evaluate the efficacy, safety, and tolerability of camizestrant combined with ribociclib in patients with ER+ HER2- advanced breast cancer who have not previously received systemic therapy for advanced disease .

Approximately 150 participants will be enrolled, and all enrolled participants will receive standard daily oral doses of camizestrant 75 mg and ribociclib 600 mg until treatment discontinuation.

03

Conditions studied

  • ER-Positive HER2-Negative Breast Cancer

Keywords

  • Metastatic
  • Breast Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Breast Diseases
  • Next Generation Oral SERD
  • Antineoplastic Agents
  • Estrogen Receptor Antagonists
  • Camizestrant
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed .
  2. Female or male, must be ≥ 18 years or as per locally allowed age limit for screening.

    Type of Participant and Disease Characteristics

  3. or cytologically documented diagnosis of ER+, - BC based on local laboratory results and who are not amenable to resection or radiation therapy with curative intent.
  4. Previously untreated with any systemic anti-cancer therapy for their locoregionally recurrent or ER+ disease.
  5. De novo Stage 4 disease, or recurrence from early CD stage breast cancer after having received standard endocrine therapy. Note that at least 12 months must have elapsed since the patient's last dose of adjuvant AI therapy without disease progression on treatment. Note that a 2-week is required after the last dose of tamoxifen prior to randomisation.
  6. performance status of 0 or 1.
  7. Adequate organ and marrow function. Sex and /Barrier Requirements
  8. For those female or male patients who are not abstinent (in line with their preferred and usual lifestyle choice), and intend to be heterosexually active with a partner:

Female patients must be using highly effective contraceptive measures from the time of screening until 4 weeks after discontinuation of study treatment, and must have a negative serum pregnancy test before first dose of any study treatment if they are of ; or must have evidence of nonchild-bearing potential by fulfilling one of the following criteria at screening:

(a) , defined as women with cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause: (i) Age ≥ 60 years (ii) Age \< 60 years with serum estradiol and FSH level within the laboratory's reference range for post-menopausal females (iii) Previous bilateral surgical oophorectomy (iv) Medically confirmed ovarian failure OR (b) Pre/peri-menopausal, ie, not meeting the criteria for being post-menopausal.

(i) Pre-/peri-menopausal women can be enrolled if amenable to be treated with monthly LHRH agonists (goserelin or leuprorelin [also known as leuprolide]). Patients must have concomitant treatment with LHRH agonists (goserelin or leuprorelin [leuprolide]) before or on the same day as the first dose of study treatment - and must be willing to continue on it for the duration of the study.

Non sterilised male partners of a patient who is a woman of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) throughout this period.

Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or using an acceptable method of contraception from the time of screening throughout the total duration of the programme and the drug washout period to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period.

Male patients can be enrolled if amenable to be treated with monthly LHRH agonists (goserelin or leuprorelin [also known as leuprolide]) unless the patients have clear orchiectomy medical history. Willingness to use 2 non-hormonal based methods of contraception throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. Participants who are not clinically indicated for endocrine therapy in combination with the CDK4/6 inhibitor ribociclib.
  2. No evidence of advanced inoperable disease, or bone only disease with sclerotic/osteoblastic bone lesions only per standard of care imaging.
  3. Have advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term, and/or pulmonary lymphangitis.
  4. Persistent treatment-induced non-haematological toxicities ( Grade > 2).
  5. Known active infection including tuberculosis and .
  6. Known to have tested positive for . Participants with HIV may be enrolled if they fulfil the criteria recommended by FDA and ASCO guidelines.
  7. Any abnormalities in heart conduction patterns; participants with pacemakers or medically controlled atrial fibrillation are not excluded.
  8. Ongoing symptomatic hypotension.
  9. Pregnant or lactating women or patients not willing to use highly effective as defined in the protocol.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Camizestrant and Ribociclib

    Patients will receive the standard dose of camizestrant and ribociclib once daily as oral tablets

    Drug: Camizestrant · Drug: Ribociclib

Interventions

  • Patients will receive the standard dose of camizestrant once daily as oral tablets

    Also known as: AZD9833

  • Patients will receive the standard dose of ribociclib once daily as oral tablets

    Also known as: KISQALI®

06

What researchers measure

Primary outcomes

  1. Efficacy of camizestrant and ribociclib by time to next treatment (TTNT)

    TTNT is defined as time from the date of the first administration of study treatment to the earliest start date of subsequent anti-cancer medication or death. The primary measure of interest is the TTNT event-free rate at 2 years.

    Time frame: Following first dose of study treatment until earliest of subsequent therapy, death and 2 years after first dose of study treatment.

Secondary outcomes

  1. Efficacy of camizestrant and ribociclib by time to discontinuation (TTD)

    TTD is defined as time from the date of the first administration of study treatment to the earliest date of camizestrant treatment discontinuation or death. The primary measure of interest is the TTD event-free rate at 2 years.

    Time frame: Following first dose of study treatment until earliest of discontinuation of camizestrant, death and 2 years after first dose of study treatment

  2. Efficacy of camizestrant and ribociclib by progression free survival (PFS)

    PFS is defined as time from first dose of study treatment until progression per RECIST 1.1 as assessed by investigator or death due to any cause. The primary measures of interest are the PFS event-free rates at 1 and 2 years.

    Time frame: Following first dose of study treatment until earliest of death, disease progression, and 2 years after first dose of study treatment.

  3. CTCAE grade ≥ 3 associated with camizestrant and ribociclib within first 6 months of study treatment

    Incidence of Grade \>=3 CTCAEs associated with Camizestrant and/or Ribo within first 6 months of receiving study treatment.

    Time frame: Following first dose of study treatment until 6 months later

07

Study locations

4 of 89 sites recruiting
  • Research Site
    Duarte, California 91010, United States
    Not yet recruiting
  • Research Site
    Palo Alto, California 94304, United States
    Not yet recruiting
  • Research Site
    Marietta, Georgia 30060, United States
    Recruiting
  • Research Site
    Evanston, Illinois 60201, United States
    Not yet recruiting
  • Research Site
    Edgewood, Kentucky 41017, United States
    Recruiting
  • Research Site
    Louisville, Kentucky 40202, United States
    Not yet recruiting
  • Research Site
    Reno, Nevada 89502, United States
    Not yet recruiting
  • Research Site
    Sioux Falls, South Dakota 57105, United States
    Not yet recruiting
  • Research Site
    Nashville, Tennessee 37204, United States
    Not yet recruiting
  • Research Site
    Fort Worth, Texas 76104, United States
    Recruiting
  • Research Site
    Kingwood, Texas 77339, United States
    Recruiting
  • Research Site
    Midlothian, Virginia 23114, United States
    Not yet recruiting
  • Research Site
    Angers, 49933, France
    Not yet recruiting
  • Research Site
    Bayonne, 64109, France
    Not yet recruiting
  • Research Site
    Bobigny, 93000, France
    Not yet recruiting
  • Research Site
    Caen, 14000, France
    Not yet recruiting
  • Research Site
    Chambray-lès-Tours, 37170, France
    Not yet recruiting
  • Research Site
    Grenoble, 38043, France
    Not yet recruiting
  • Research Site
    Montpellier, 34070, France
    Not yet recruiting
  • Research Site
    Nancy, 54100, France
    Not yet recruiting
  • Research Site
    Nîmes, 30029, France
    Not yet recruiting
  • Research Site
    Paris, 75014, France
    Not yet recruiting
  • Research Site
    Pierre-Bénite, 69310, France
    Not yet recruiting
  • Research Site
    Valenciennes, 59300, France
    Not yet recruiting
  • Research Site
    Vandœuvre-lès-Nancy, 54519, France
    Not yet recruiting
  • Research Site
    Villejuif, 94805, France
    Not yet recruiting
  • Research Site
    Berlin, 13125, Germany
    Not yet recruiting
  • Research Site
    Düsseldorf, 40235, Germany
    Not yet recruiting
  • Research Site
    Erlangen, 91054, Germany
    Not yet recruiting
  • Research Site
    Freiburg im Breisgau, 79110, Germany
    Not yet recruiting
  • Research Site
    Mönchengladbach, 41061, Germany
    Not yet recruiting
  • Research Site
    München, 81675, Germany
    Not yet recruiting
  • Research Site
    Paderborn, 33098, Germany
    Not yet recruiting
  • Research Site
    Trier, 54290, Germany
    Not yet recruiting
  • Research Site
    Velbert, 42551, Germany
    Not yet recruiting
  • Research Site
    Aviano, 33081, Italy
    Not yet recruiting
  • Research Site
    Bergamo, 24127, Italy
    Not yet recruiting
  • Research Site
    Genova, 16132, Italy
    Not yet recruiting
  • Research Site
    Milan, 20127, Italy
    Not yet recruiting
  • Research Site
    Naples, 80131, Italy
    Not yet recruiting
  • Research Site
    Gdansk, 80-952, Poland
    Not yet recruiting
  • Research Site
    Konin, 62-500, Poland
    Not yet recruiting
  • Research Site
    Krakow, 30-688, Poland
    Not yet recruiting
  • Research Site
    Lodz, 90-302, Poland
    Not yet recruiting
  • Research Site
    Lublin, 20-090, Poland
    Not yet recruiting
  • Research Site
    Poznan, 61-485, Poland
    Not yet recruiting
  • Research Site
    Przemyśl, 37-700, Poland
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Wroclaw, 53-413, Poland
    Not yet recruiting
  • Research Site
    Cheonan-si, 31151, South Korea
    Not yet recruiting
  • Research Site
    Daegu, 42415, South Korea
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Goyang-si, 10408, South Korea
    Not yet recruiting
  • Research Site
    Hwasun-eup, 58128, South Korea
    Not yet recruiting
  • Research Site
    Incheon, 405-760, South Korea
    Not yet recruiting
  • Research Site
    Seongbuk-Gu, 02841, South Korea
    Not yet recruiting
  • Research Site
    Seongnam-si, 13520, South Korea
    Not yet recruiting
  • Research Site
    Seongnam-si, 13620, South Korea
    Not yet recruiting
  • Research Site
    Seoul, 03080, South Korea
    Not yet recruiting
  • Research Site
    Seoul, 06273, South Korea
    Not yet recruiting
  • Research Site
    Seoul, 06351, South Korea
    Not yet recruiting
  • Research Site
    Seoul, 06591, South Korea
    Not yet recruiting
  • Research Site
    Seoul, 07985, South Korea
    Not yet recruiting
  • Research Site
    Seoul, 3722, South Korea
    Not yet recruiting
  • Research Site
    Songpa-gu, 05505, South Korea
    Not yet recruiting
  • Research Site
    Suwon, 16499, South Korea
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Badajoz, 06080, Spain
    Not yet recruiting
  • Research Site
    Badalona, 08916, Spain
    Not yet recruiting
  • Research Site
    Barcelona, 08041, Spain
    Not yet recruiting
  • Research Site
    Burgos, 9006, Spain
    Not yet recruiting
  • Research Site
    Donostia / San Sebastian, 20014, Spain
    Not yet recruiting
  • Research Site
    Huelva, 21005, Spain
    Not yet recruiting
  • Research Site
    Jaén, 23007, Spain
    Not yet recruiting
  • Research Site
    Las Palmas de Gran Canaria, 35016, Spain
    Not yet recruiting
  • Research Site
    Majadahonda, 28222, Spain
    Not yet recruiting
  • Research Site
    Málaga, 29010, Spain
    Not yet recruiting
  • Research Site
    Murcia, 30008, Spain
    Not yet recruiting
  • Research Site
    Oviedo, 33011, Spain
    Not yet recruiting
  • Research Site
    Palma de Mallorca, 07198, Spain
    Not yet recruiting
  • Research Site
    Pontevedra, 36312, Spain
    Not yet recruiting
  • Research Site
    Pozuelo de Alarcón, 28223, Spain
    Not yet recruiting
  • Research Site
    Santander, 39008, Spain
    Not yet recruiting
  • Research Site
    Toledo, 45007, Spain
    Not yet recruiting
  • Research Site
    Zaragoza, 50009, Spain
    Not yet recruiting
  • Research Site
    Basel, 4031, Switzerland
    Not yet recruiting
  • Research Site
    Liestal, CH-4410, Switzerland
    Not yet recruiting
  • Research Site
    Rennaz, 1847, Switzerland
    Not yet recruiting
  • Research Site
    Abu Dhabi, 11241, United Arab Emirates
    Not yet recruiting
  • Research Site
    Al Ain City, 00000, United Arab Emirates
    Not yet recruiting
  • Research Site
    Dubai, 505004, United Arab Emirates
    Not yet recruiting
  • Research Site
    Mohammed Bin Zayed City, 92510, United Arab Emirates
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Feb 2029, 32 months after the start.

Of 83 industry-sponsored phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 57. This study's planned 32 months is below that.

Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
Jun 15, 2026
StartActual
Jun 15, 2026
Primary completionEst.
Feb 28, 2029
CompletionEst.
Feb 28, 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Research Site · Edgewood, United StatesNot yet recruiting→Recruiting
  • Research Site · Fort Worth, United StatesNot yet recruiting→Recruiting
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Research Site · Edgewood, United StatesNot yet recruiting→Recruiting
    • Research Site · Fort Worth, United StatesNot yet recruiting→Recruiting
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07647328
Lead sponsor
AstraZeneca
Collaborators
ICON plc
Responsible party
Sponsor
First posted
Jun 15, 2026
Start date
Jun 15, 2026
Primary completion
Feb 28, 2029 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Oct 19, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9833

Start the discussion